{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:39:55Z","timestamp":1771011595221,"version":"3.50.1"},"reference-count":29,"publisher":"Impact Journals, LLC","issue":"53","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,10,31]]},"DOI":"10.18632\/oncotarget.18114","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T20:04:37Z","timestamp":1495569877000},"page":"91703-91710","source":"Crossref","is-referenced-by-count":24,"title":["Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed\/refractory Hodgkin\u2019s lymphoma"],"prefix":"10.18632","volume":"8","author":[{"given":"Cinzia","family":"Pellegrini","sequence":"first","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Broccoli","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Pulsoni","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Hematology, Sapienza University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Rigacci","sequence":"additional","affiliation":[{"name":"Department of Hematology, University and Hospital Careggi, Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Patti","sequence":"additional","affiliation":[{"name":"Department of Hematology, Azienda Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Gini","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ospedali Riuniti di Ancona, Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Mannina","sequence":"additional","affiliation":[{"name":"Hematology Unit, Ospedale Papardo, Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[{"name":"Hematology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Rusconi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Niguarda Hospital, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Romano","sequence":"additional","affiliation":[{"name":"Division of Hematology, AOU, Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Vanazzi","sequence":"additional","affiliation":[{"name":"European Institute of Oncology, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Botto","sequence":"additional","affiliation":[{"name":"Hematology, Azienda Ospedaliera Universitaria Citt\u00e0 della Salute e della Scienza, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"Oncology and Hematology, Humanitas Cancer Center, Rozzano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Hoaus","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Catholic University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Matteo","family":"Rigolin","sequence":"additional","affiliation":[{"name":"Hematology Section, St. Anna University Hospital, Cona, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[{"name":"Scientific Direction, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Pz, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizio","family":"Mazza","sequence":"additional","affiliation":[{"name":"Ospedale Moscati, Department of Hematology-Oncology, Taranto, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Molica","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ciaccio-Pugliese Hospital, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Fama","sequence":"additional","affiliation":[{"name":"Hematology Unit, Arcispedale Santa Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Gaudio","sequence":"additional","affiliation":[{"name":"Hematology Unit, Policlinico di Bari, Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Merli","sequence":"additional","affiliation":[{"name":"Hematology, Ospedale di Circolo, Fondazione Macchi, Varese, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fioravante","family":"Ronconi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Gritti","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Vallisa","sequence":"additional","affiliation":[{"name":"Division of Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Tosi","sequence":"additional","affiliation":[{"name":"Hematology Unit, Infermi Hospital Rimini, Rimini, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Marina","family":"Liberati","sequence":"additional","affiliation":[{"name":"Hematology, Ospedale Perugia, Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonello","family":"Pinto","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione Pascale, IRCCS, Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Pavone","sequence":"additional","affiliation":[{"name":"Division of Hematology, Ospedale G. Panico, Tricase, Lecce, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Gherlinzoni","sequence":"additional","affiliation":[{"name":"Hematology Unit, Ca\u2019 Foncello Hospital, Treviso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Paola","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Sant\u2019Andrea Hospital, Sapienza University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Volpetti","sequence":"additional","affiliation":[{"name":"Department of Hematology, DISM, Azienda Sanitaria Universitaria Integrata, Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology and Clinical Immunology Unit, University of Padua, Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cecilia","family":"Goldaniga","sequence":"additional","affiliation":[{"name":"Onco-Hematology Unit, Fondazione Ca\u2019 Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Bonfichi","sequence":"additional","affiliation":[{"name":"Hematology, IRCCS Policlinico San Matteo, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"De Renzo","sequence":"additional","affiliation":[{"name":"Hematology, AOU Federico II Napoli, Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Schiavotto","sequence":"additional","affiliation":[{"name":"Hematology, San Bortolo Hospital, Vicenza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Spina","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology A, National Cancer Institute, Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo Michele","family":"Carella","sequence":"additional","affiliation":[{"name":"Division of Hematology 1, IRCCS A.O.U. San Martino IST, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Stefoni","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,5,23]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","article-title":"Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant","volume":"54","author":"Horning","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdi003","article-title":"Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)","volume":"16","author":"Engert","year":"2005","journal-title":"Ann Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804","volume":"18","author":"Canellos","year":"2007","journal-title":"Ann Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cncr.21587","article-title":"Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma","volume":"106","author":"Crump","year":"2006","journal-title":"Cancer"},{"key":"5","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1080\/10428194.2017.1300898","article-title":"Novel agents in classical Hodgkin lymphoma","volume":"58","author":"von Tresckow","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/joim.12582","article-title":"Novel treatment concepts in Hodgkin lymphoma","volume":"281","author":"Diepstra","year":"2017","journal-title":"J Intern Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2009.07727.x","article-title":"Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma","volume":"146","author":"Moskowitz","year":"2009","journal-title":"Br J Haematol"},{"key":"8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bbmt.2011.07.020","article-title":"Outcomes of Hodgkin\u2019s lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation","volume":"18","author":"Anagnostopoulos","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin\u2019s lymphoma","volume":"9","author":"K\u00fcppers","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1034\/j.1600-0609.2002.01721.x","article-title":"Hodgkin\u2019s lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy","volume":"68","author":"Rombos","year":"2002","journal-title":"Eur J Haematol"},{"key":"11","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Connors","year":"2012","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/blood-2012-05-430918","article-title":"Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience","volume":"120","author":"Engert","year":"2012","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.critrevonc.2015.03.011","article-title":"Experience of brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma and relapsed\/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: review of the literature","volume":"95","author":"Bonthapally","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"14","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3324\/haematol.2012.083048","article-title":"Brentuximab vedotin in relapsed\/refractory Hodgkin\u2019s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials","volume":"98","author":"Derenzini","year":"2013","journal-title":"Haematologica"},{"key":"15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3324\/haematol.2012.069393","article-title":"Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center","volume":"98","author":"Radford","year":"2013","journal-title":"Haematologica"},{"key":"16","first-page":"1717","article-title":"Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia","volume":"7","author":"Kim","year":"2014","journal-title":"Onco Targets Ther"},{"key":"17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00277-014-2215-9","article-title":"Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey","volume":"94","author":"Topcuoglu","year":"2015","journal-title":"Ann Hematol"},{"key":"18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3324\/haematol.2015.134213","article-title":"Impact of post-brentuximab vedotin consolidation on relapsed\/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program","volume":"101","author":"Brice","year":"2016","journal-title":"Haematologica"},{"key":"19","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1182\/blood-2012-03-418673","article-title":"Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma","volume":"119","author":"Gopal","year":"2012","journal-title":"Blood"},{"key":"20","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3109\/10428194.2014.930852","article-title":"Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"56","author":"Advani","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"21","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Younes","year":"2015","journal-title":"Blood"},{"key":"22","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Younes","year":"2016","journal-title":"Blood"},{"key":"23","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1634\/theoncologist.2016-0112","article-title":"Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients","volume":"21","author":"Zinzani","year":"2016","journal-title":"Oncologist"},{"key":"24","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3109\/10428194.2013.876496","article-title":"Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy","volume":"55","author":"Fanale","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"25","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood.V126.23.587.587","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Yasenchak","year":"2015","journal-title":"Blood"},{"key":"26","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed\/Refractory Hodgkin Lymphoma","volume":"21","author":"Leonard","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 1","key":"27","first-page":"7","article-title":"Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed\/Refractory HL Prior to AHCT","volume":"14","author":"Forman","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1002\/hon","article-title":"Reporting real-life experience with drugs in lymphoma patients","author":"Zinzani","year":"2016","journal-title":"Hematol Oncol"},{"key":"29","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Lister","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.18114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T17:15:25Z","timestamp":1596734125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.18114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,23]]},"references-count":29,"journal-issue":{"issue":"53","published-print":{"date-parts":[[2017,10,31]]}},"alternative-id":["18114","29207679"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.18114","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,23]]}}}